Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
DOI:
https://doi.org/10.25305/unj.132316Abstract
No abstract.
References
Гусев Е.И., Бойко А.Н. Рассеянный склероз: от изучения иммунопатогенеза к новым методам лечения. — М., 2001. — 128 с.
Гусев Е.И., Демина Т.Л., Бойко А.Н. Рассеянный склероз. — М., 1997. — 463 с.
Гусев Е.И., Дробышева Н.А., Никифоров А.С. Лекарственные средства в неврологии. — М., 1998.
Жученко Т.Д., Завалишин И.А. Лечение рассеянного склероза // Неврол. журн. — 1996. — №1. — С.37–43.
Жученко Т.Д., Шмидт Т.Е. Копаксон — новое средство для лечения рассеянного склероза // Вестн. практ. неврологии. — 1998. — №4. — С.194–196.
Корчагин В.П., Нарожная В.Л. Экономическая оценка от людских потерь // Пробл. прогнозирования. — 1998. — №5. — С.109–120.
Машковский М.Д. Лекарственные средства. — 14-е изд. — М.: Медицина, 2000. — Т.1.
Население России 1999: Седьмой ежегодный демографический доклад / Под ред. А.Г. Вишневского — М., 2000.
Новик А.А., Ионова Т.И., Кайнд П. Концепция исследования качества жизни в медицине. — СПб: ЭЛБИ, 1999.
Рассеянный склероз. Избранные вопросы теории и практики / Под. ред. И.А. Завалишина, В.И. Головкина. — М., 2000. — 639 с.
Рецептурный справочник врача-невролога / А.А. Скоромец, А.В. Амелин, М.В. Пчелинцев и др. — СПб., 2000.
Шварц Г.Я. Фармакоэкономическое обоснование применения лекарственных препаратов превентивного ряда в лечении больных рассеянным склерозом // Неврол. журн. — 2001. — №1. — С.43–47.
Шток В.Н. Фармакотерапия в неврологии. — М.: МИА, 300 с.
Comi L., Filippi M. The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting MS (RRMS): a multi-center, randomized, double-blind, placebo-controlled study extended by open-label results // Neurology. — 1999. — V.52, suppl.2. — A289.
Hauser S.L. Multiple sclerosis and other demyelinating diseases // Harrison' s principles in internal medicine / Eds. K.L. Isselbacher et al. — 13th ed. — N.Y.: McGraw-Hills Inc., 1994. — P.2281–2294.
Henriksson F., Johnson B. The economic evaluation and consequences of multiple sclerosis // MSJ. — 2000. — V.7, N1. — P.9–17.
Holmes J., Madwick N., Bates D. The cost of multiple sclerosis // Brit. J. Med. Econ. — 1995. — V.8. — P.181–193.
Johnson K.P., Brooks B.R., Cohen J.A. et al. Copolimer I reduces rate and impruves disability in relapsing-remitting multiple sclerosis: results of phase III multicenter, double-blind placebo-controlled trial // Neurology. — 1995. — V.45. — P.1268–1276.
Johnson K.P., Brooks B.R., Cohen J.A. et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and mantains its clinical effect on multiple sclerosis relapse rate and degree of disability // Neurology. — 1998. — V.50. — P.701–708.
Kendrick M., Johnson K.P. Long-term treatment of multiple sclerosis with interferon-b may be cost-effective // Pharmacoeconomics. — 2000. — V.18. — P.45–53.
Mancardi G.L., Sardanelli F., Parodi R.S. et al. Effect of copolimer-I on serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis // Pharmacoeconomics. — 1998. — V.5. — P.1127–1133.
Milo R., Panitch H. Glatiramer acetate or interferon-b for multiple sclerosis? // CNS Drugs. — 1999. — V.11. — P.289–306.
Murphy N., Confavreux C., Haas J. et al. Economic evaluation of multiple sclerosis in UK, Germany and France // Pharmacoeconomics. — 1998. — V.5. — P.607–622.
Paty D.W., Li D.K.B. The UBC MS/MRI Study Group et al. Interferon-beta Ib is effective in relapsing-remitting multiple sclerosis. II.MRI analyses results of a multicenter, randomized, double-blind placebo-controlled trial // Neurology. — 1993. — V.43. — P.662–667.
Poser S., Kurtzke J.F., Poser W. et al. Survival in multiple sclerosis // J. Clin. Epidemiol. — 1989. — V.42. — P.159–168.
The INFB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon-betaIb in the treatment of multiple sclerosis: Final outcame of the randomized controlled trial // Neurology. — 1995. — V.45. — P.1277–1285.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2005 G. Ya. Shvarts
This work is licensed under a Creative Commons Attribution 4.0 International License.
Ukrainian Neurosurgical Journal abides by the CREATIVE COMMONS copyright rights and permissions for open access journals.
Authors, who are published in this Journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the Journal under the terms of Creative Commons Attribution License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this Journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form of which it has been published by the Journal (for example, to upload the work to the online storage of the Journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this Journal is included.
